Research article · 28 Aug 2020
Conference abstractPublished 21 Oct 2013
Quality risk management system
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
How often does this happen with you? Your product is developed and ready for scale-up... and there is a last minute change of manufacturing site! Reasons provided could be one or many of the following- ?Our Operations is way too loaded? or ?We are running back orders, hence can?t take up more? or ?Getting this manufactured at a contract location works better for our bottom line.? These reasons are absolutely valid for business, but they create havoc among product developers i.e. R&D personnel. The situation aggravates further when R&D finds out that, their process was developed using an ?Octagonal? blender, while the manufacturing site has only a ?V? blender. Further, there is no time to procure and qualify a new blender... and there is no way that ?Filing date? can be moved ... WoW...!! Such situations are when QRMS (Quality Risk Management Systems) are the only scientific saviours! This paper captures use of QRMS to situations such as above and similar, practical and commonly occurring scenarios within the pharmaceutical industry. Theoretically, QRMS can be applied to both (a) regulators and (b) manufacturers. This paper, however, shall cover aspects of QRMS as applied to the latter. As QRMS is an overall and continuous process of minimizing risk to product quality throughout its life cycle, QRMS is therefore, applicable both proactively and retrospectively. This paper shall cover- both proactive and retrospective aspects of QRMS, Verification of a QRM plan, Risk Management tools and Real- life case studies. Following case studies are being discussed at length- (a) Proactive QRMS: I. Quality-by-design (QbD) during drug- product development. II. QbD during stability studies. III. Risk Analysis prior to a process scale-up. (b) Retrospective QRMS: Internal audits, CAPA etc.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 21 Jun 2018
Driven strategy for effective monitoring pharmacovigilance quality system – key pointChallenges in pharmacovigilance of vaccines in clinical trials and risk management strategies
Conference abstract · 2018
Quality risk management system
Conference abstract · 25 Sep 2017
Quality risk management system
Conference abstract · 12 Aug 2016
Quality risk management system
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Shruti U. Bhat”

